Skip to content

US · BNR · MEDICAL - DIAGNOSTICS & RESEARCH

Burning Rock Biotech Limited (BNR) intrinsic value and stock valuation

$13.24as of 2026-11-21 · Mkt cap 9.39M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Burning Rock Biotech Limited DCF and intrinsic value

InvestorsCraft values BNR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BNR’s statements →

Burning Rock Biotech Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Guangzhou, GD 510005 brbiotech.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$539.6M+4.6% 5y CAGRd
20172025
Net income
-$-55.35M
20172025
Free cash flow
-$-33.69M
20172025
Total equity
$535.6M-26% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$539.6M$515.8M$537.4M$563.2M$507.9M
Operating income-$-54.84M-$-357.56M-$-669.32M-$-980.41M-$-797.06M
Net income-$-55.35M-$-346.63M-$-653.69M-$-971.23M-$-796.7M
EPSd-$-51.25M-$-33.69M-$-63.84M-$-93.48M-$-76.46M
Operating cash flow-$-28.44M-$-92.26M-$-255.78M-$-456.81M-$-477.89M
Capital expenditure-$-5.25M-$-5.98M-$-9.38M-$-62.03M-$-213.45M
Free cash flow-$-33.69M-$-98.24M-$-265.17M-$-518.84M-$-691.33M
Total assets$820.9M$885.3M$1.04B$1.59B$2.28B
Total debt$43.2M$52.3M$12.3M$50.8M$86.7M
Net debt-$-438.25M-$-467.53M-$-602.77M-$-854.66M-$-1.34B
Total equity$535.6M$580.8M$768.4M$1.16B$1.85B
Cash and short-term investments$481.4M$519.9M$615.1M$905.5M$1.5B
Income statement
20252024202320222021
Revenue$539.6M$515.8M$537.4M$563.2M$507.9M
Cost of revenue$136.7M$153.4M$174.2M$183.2M$143.7M
Gross profit$402.9M$362.4M$363.2M$380M$364.2M
Research and development expenses$166.5M$232.3M$347M$421.9M$367.9M
Selling, general and administrative expenses$291.3M$452.5M$685.5M$938.6M$793.4M
Other expenses$0.00$35.1M$0.00$0.00$0.00
Operating expenses$457.8M$720M$1.03B$1.36B$1.16B
Cost and expenses$594.4M$873.4M$1.21B$1.54B$1.3B
Interest income$8.05M$12.2M$18M$9.46M$3.46M
Interest expense$30K$0.00$0.00$0.00$1.54M
Depreciation and amortization$21.8M$52.2M$133.4M$124.1M$47.8M
Ebitda-$-32M-$-270.23M-$-517.9M-$-845.15M-$-746.5M
Operating income-$-54.84M-$-357.56M-$-669.32M-$-980.41M-$-797.06M
Total other income/expenses, net$1.05M$16.8M$18M$11.2M$1.27M
Income before tax-$-53.79M-$-340.74M-$-651.3M-$-969.25M-$-795.8M
Income tax expense$1.56M$5.88M$2.39M$1.99M$900K
Net income-$-55.35M-$-346.63M-$-653.69M-$-971.23M-$-796.7M
Weighted average shares outstanding$1.08M$10.3M$10.2M$10.4M$10.4M
Weighted average diluted shares outstanding$1.08M$10.3M$10.2M$10.4M$10.4M
Balance sheet
20252024202320222021
Cash and short-term investments$481.4M$519.9M$615.1M$905.5M$1.5B
Net receivables$182M$173.5M$149.6M$170.2M$161.4M
Inventory$57M$53.8M$69M$130.3M$123.2M
Total current assets$739.1M$776.6M$884.1M$1.26B$1.82B
Property, plant and equipment, net$73.9M$100.3M$144.2M$300M$406.4M
Goodwill and intangible assets$280K$420K$960K$1.99M$5.15M
Long-term investments$0.00$0.00$340K$690K$910K
Total non-current assets$81.8M$108.7M$155.9M$328.7M$457.6M
Total assets$820.9M$885.3M$1.04B$1.59B$2.28B
Accounts payable$40.8M$33.8M$18.1M$51M$63.1M
Short-term debt$17M$24.6M$8.63M$37.2M$37.4M
Deferred revenue$107.9M$118.5M$131.7M$149.4M$143.8M
Total current liabilities$247.1M$266.3M$263.4M$411.5M$372.2M
Long-term debt$26.2M$27.8M$3.69M$13.6M$49.3M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$38.2M$38.2M$8.23M$17.7M$61.1M
Capital lease obligations$41.2M$52.3M$12.3M$50.8M$84.3M
Total liabilities$285.3M$304.5M$271.6M$429.1M$433.3M
Common stock$140K$140K$140K$140K$140K
Retained earnings-$-4.26B-$-4.2B-$-3.85B-$-3.2B-$-2.23B
Accumulated other comprehensive income (loss)-$-162.24M-$-158.05M-$-161.53M-$-165.72M-$-207.07M
Total equity$535.6M$580.8M$768.4M$1.16B$1.85B
Total investments$0.00$0.00$340K$690K$64.7M
Total debt$43.2M$52.3M$12.3M$50.8M$86.7M
Net debt-$-438.25M-$-467.53M-$-602.77M-$-854.66M-$-1.34B
Cash flow statement
20252024202320222021
Net income-$-55.35M-$-346.63M-$-653.69M-$-971.23M-$-796.7M
Depreciation and amortization$21.8M$52.2M$133.4M$124.1M$47.8M
Stock-based compensation$13.9M$155.6M$260.7M$326.8M$282.4M
Change in working capital-$-59.39M-$-36.53M-$-52.16M-$-11.16M-$-62.4M
Accounts receivable-$-33.23M-$-26.8M-$-12.39M-$-42.16M-$-18.93M
Inventory$2.5M$2.51M$57.3M-$-21.65M-$-67M
Accounts payable$7.18M$18.9M-$-31.12M$16.6M-$-5.1M
Net cash provided by operating activities-$-28.44M-$-92.26M-$-255.78M-$-456.81M-$-477.89M
Investments in property, plant and equipment-$-5.25M-$-5.42M-$-8.1M-$-62.03M-$-213.45M
Acquisitions, net$0.00$0.00$0.00$0.00$2.53M
Net cash used for investing activities-$-4.39M-$-4.41M-$-9.3M-$-7.46M$81.7M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-70K-$-6.98M-$-71.83M-$-4.27M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.9M-$-70K-$-48.83M-$-86.24M-$-52.9M
Net change in cash-$-41.07M-$-93.05M-$-310.05M-$-513.84M-$-486.09M
Cash at end of period$481.1M$522.2M$615.2M$925.3M$1.44B
Operating cash flow-$-28.44M-$-92.26M-$-255.78M-$-456.81M-$-477.89M
Capital expenditure-$-5.25M-$-5.98M-$-9.38M-$-62.03M-$-213.45M
Free cash flow-$-33.69M-$-98.24M-$-265.17M-$-518.84M-$-691.33M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Burning Rock Biotech Limited

        Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.

        CEO
        Yusheng Han
        Employees
        667
        Beta
        1.33

        Explore

        Frequently asked questions

        What is the intrinsic value of Burning Rock Biotech Limited (BNR)?

        InvestorsCraft does not currently publish an intrinsic value for BNR. How the IC value is calculated.

        Is BNR undervalued?

        InvestorsCraft does not publish an undervaluation signal for BNR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.